MWA
CRL icon

Medallion Wealth Advisors’s Charles River Laboratories CRL Stock Holding History

Medallion Wealth Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.07K Hold
12
– – ﹤0.01% 993
2025
Q4 		$2.39K Hold
12
– – ﹤0.01% 970
2025
Q3 		$1.88K Hold
12
– – ﹤0.01% 988
2025
Q2 		$1.85K Hold
12
– – ﹤0.01% 965
2025
Q1 		$1.75K Hold
12
– – ﹤0.01% 938
2024
Q4 		$2.21K Buy
+12
New +$2.31K ﹤0.01% 847

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Medallion Wealth Advisors's CRL Position: Q1 2026 in Review

Medallion Wealth Advisors held its Charles River Laboratories (CRL) position steady in Q1 2026 at 12 shares worth $2.07K. The position accounts for ﹤0.01% of the portfolio, ranked #993.

Medallion Wealth Advisors first reported a position in CRL in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.39K in Q4 2025. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Medallion Wealth Advisors held 12 shares of Charles River Laboratories worth $2.07K as of Q1 2026.
  • Medallion Wealth Advisors left its Charles River Laboratories share count unchanged in Q1 2026.
  • Charles River Laboratories made up ﹤0.01% of Medallion Wealth Advisors's portfolio in Q1 2026, its #993 holding.
  • Medallion Wealth Advisors first reported a position in Charles River Laboratories in Q4 2024 and has held it in 6 quarters since.
  • Medallion Wealth Advisors's Charles River Laboratories position peaked at $2.39K in Q4 2025.
  • 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Medallion Wealth Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.